Stocks
Allogene Therapeutics (ALLO) EV/EBITDA US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EV/EBITDA | ? | -9.68 | 1.30 | 1.13 | -0.88 | -0.76 | -1.75 | ||
| Changes by years, y/y, % | +2% | -113% | -13% | -178% | -13% | -39.6% | |||
Allogene Therapeutics. EV/EBITDA
Allogene Therapeutics. EV/EBITDA, changes, %
Allogene Therapeutics (ALLO) EV/EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EV/EBITDA | ? | -0.49 | -0.24 | -0.55 | -0.76 | -2.50 | -1.75 | |
| Changes by years, y/y, % | -145% | -117% | -63% | -25% | +414% | |||
| Changes by quarters, q/q, % | -52% | -51% | +128% | +40% | +227% | |||
